Verona Pharma plc (VRNA) Financial Analysis & Valuation | Quarter Chart
Company facts
Reported company information and share structure.
| Market Cap | $72.68B | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | GB | CEO | David S. Zaccardelli |
| IPO Date | 2017-04-28 | CAGR | — |
| Employees | 209 | Website | www.veronapharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.15% | Total Yield | 0.15% |
Key metrics
Reported fundamentals and market-derived technical indicators.
| EV | $7.91B | P/E | -102.8 | Forward P/E | — | PEG | — |
| P/S | 444.67 | P/B | 32.9 | P/CF | -930.9 | P/FCF | -7008.07 |
| Sales | $167.65M | Sales 1Y | — | Sales 3Y | 464.8% | Sales 5Y | — |
| EPS | $-1.04 | EPS 1Y | — | EPS 3Y | — | EPS 5Y | — |
| Sales QoQ | 27.3% | EPS QoQ | -166.67% | Sales QoQ Avg | — | EPS QoQ Avg | -69.59% |
| Gross Margin | 95.27% | Operating Margin | -7.92% | Profit Margin | -18.95% | ROCE | -2.48% |
| ROA | -5% | ROE | -13% | Altman Z Score | 109.91 | Piotroski Score | 3 |
| Current Ratio | 10.71 | Quick Ratio | 10.54 | Cash Ratio | 8.55 | Op. CF Ratio | 0.6 |
| Debt/Equity | 0.88 | Debt/Assets | 0.43 | Lt Debt/Equity | 0.87 | Lt Debt/Cap. | 0.47 |
| Intrst Cov. | -0.47 | Inventory Turnover | 0.9 | Asset Turnover | 0.29 | Receivables Turnover | 1.88 |
| Enterprise Value | $7.91B | P/E Ratio | -102.8 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 444.67 | P/B Ratio | 32.9 |
| P/CF Ratio | -930.9 | P/FCF Ratio | -7008.07 |
| EPS | $-1.04 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | 0.95% |
| Operating Margin | -0.08% | Profit Margin | -0.19% |
| ROE | -0.13% | ROA | -0.05% |
| ROCE | -0.02% | Current Ratio | 10.71 |
| Quick Ratio | 10.54 | Cash Ratio | 8.55 |
| Debt/Equity | 0.88 | Interest Coverage | -0.47 |
| Altman Z Score | 109.91 | Piotroski Score | 3 |
Verona Pharma plc (VRNA) valuation & financials
Verona Pharma plc (VRNA) has a market capitalization of $72.68B and trades at a price-to-earnings ratio of -102.8. It operates in the Healthcare sector (Biotechnology).
Verona Pharma plc's next earnings report is scheduled for November 3, 2025; analysts estimate EPS of $0.16. Check the earnings calendar to see all companies reporting this week.
Verona Pharma plc (VRNA) — frequently asked questions
When does Verona Pharma plc (VRNA) report earnings next?
Verona Pharma plc is expected to report earnings on November 3, 2025. Analysts estimate EPS of $0.16.
What is Verona Pharma plc's market cap?
Verona Pharma plc (VRNA) has a market capitalization of $72.68B.
What is VRNA's P/E ratio?
Verona Pharma plc trades at a price-to-earnings ratio of -102.8, with trailing twelve-month EPS of $-1.04.
Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)